SCHEMBL16245548

SCHEMBL16245548

CCOC(=O)CCCOc1ccc(Nc2nc(Nc3ccc(CCCNC(=O)OC(C)(C)C)cc3)ncc2N)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ITK Q08881 3/20 0.49
▸ EGFR P00533 3/20 0.46
▸ AURKA O14965 1/20 0.41
▸ ADORA2A P29274 2/20 0.41
▸ FGFR1 P11362 1/20 0.41
▸ CA12 O43570 4/20 0.41
▸ CA1 P00915 4/20 0.41
▸ CA2 P00918 4/20 0.41
▸ CA9 Q16790 4/20 0.41
▸ JAK2 O60674 1/20 0.39
▸ SIRT5 Q9NXA8 1/20 0.39
▸ BRD4 O60885 1/20 0.39
▸ NPC1 O15118 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ IGF1R P08069 1/20 0.38
▸ SYK P43405 1/20 0.38
▸ ADRB2 P07550 1/20 0.38
▸ ADRB1 P08588 1/20 0.38
▸ ADRB3 P13945 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16245565 0.98 ITK (0.49) ITKEGFRAURKAADORA2AFGFR1
SCHEMBL16245569 0.94 ITK (0.54) ITKEGFRAURKACA12CA1
SCHEMBL16246173 0.92 ITK (0.54) ITKEGFRAURKACA12CA1
SCHEMBL16245582 0.88 GSK3B (0.47) ITKEGFRAURKAFGFR1CA12
SCHEMBL16246167 0.87 ITK (0.46) ITKEGFRJAK2BRD4
SCHEMBL16245562 0.86 GSK3B (0.47) ITKEGFRAURKAFGFR1CA12
SCHEMBL16245542 0.84 RPS6KA3 (0.52) ITKEGFRADORA2AFGFR1
SCHEMBL16245581 0.82 ITK (0.52) ITKEGFRAURKACA12CA1
SCHEMBL16245605 0.82 RPS6KA3 (0.51) ITKEGFRADORA2AFGFR1CA12
SCHEMBL16245595 0.80 ITK (0.51) ITKEGFRAURKACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9861635-B2 Macrocycles as kinase inhibitors MERCK PATENT GMBH (DE) 2018-01-09 — — US disclosed
US-9861635-B2 Macrocycles as kinase inhibitors MERCK PATENT GMBH (DE) 2018-01-09 — — US disclosed
EP-2994471-B1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2017-05-17 — — EP disclosed
EP-2994471-B1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2017-05-17 — — EP disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
EP-2994471-A1 MACROCYCLES AS KINASE INHIBITORS Merck Patent GmbH (DE) 2016-03-16 — — EP disclosed
WO-2014180524-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-11-13 — — WO disclosed
WO-2014180524-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS EIF2AK4, CDK2, CDK1 ITK 1468/4885EGFR 1412/4885AURKA 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback